Metabolic Alterations in Parkinson's Disease after Thalamotomy, as Revealed by 1H MR Spectroscopy by Baik, Hyun-Man et al.
180 Korean J Radiol 3(3), Septmeber 2002
Metabolic Alterations in Parkinson’s
Disease after Thalamotomy, as Revealed
by 
1H MR Spectroscopy
Objective: To determine, using proton magnetic resonance spectroscopy (
1H
MRS) whether thalamotomy in patients with Parkinson’s disease gives rise to sig-
nificant changes in regional brain metabolism.
Materials and Methods: Fifteen patients each underwent stereotactic thalamo-
tomy for the control of medically refractory parkinsonian tremor. Single-voxel 
1H
MRS was performed on a 1.5T unit using a STEAM sequence (TR/TM/TE,
2000/14/20 msec), and spectra were obtained from substantia nigra, thalamus
and putamen areas, with volumes of interest of 7 8ml, before and after thalamoto-
my. NAA/Cho, NAA/Cr and Cho/Cr metabolite ratios were calculated from relative
peak area measurements, and any changes were recorded and assessed.
Results: In the substantia nigra and thalamus, NAA/Cho ratios were generally
low. In the substantia nigra of 80% of patients (12/15) who showed clinical
improvement, decreased NAA/Cho ratios were observed in selected voxels after
thalamic surgery (p < 0.05). In the thalamus of 67% of such patients (10/15), sig-
nificant decreases were also noted (p < 0.05).
Conclusion: Our results suggest that the NAA/Cho ratio may be a valuable cri-
terion for the evaluation of Parkinson’s disease patients who show clinical
improvement following surgery. By highlighting variations in this ratio, 
1H MRS
may help lead to a better understanding of the pathophysiologic processes occur-
ring in those with Parkinson’s disease.
arkinson’s disease is an irreversible and progressive neurodegenerative
disease characterized by resting tremor, rigidity, bradykinesia, and pos-
tural instability (1 3). In recent years, increasing interest has been shown
in the stereotactic neurosurgical treatment (radiofrequency thalamotomy or pallidoto-
my) of the condition (4 9), and in the post-levodopa era, stereotactic thalamotomy has
been reconsidered as a viable alternative in the treatment of parkinsonian tremor (10,
11). The pathophysiology of thalamic ablation for the relief of Parkinsonism is, howev-
er, not completely understood, and little information about the changes in regional
brain metabolism occurring after thalamotomy in Parkinson’s disease is available.
In-vivo proton magnetic resonance spectroscopy (
1H MRS) is a noninvasive tech-
nique that allows in-vivo assessment of brain tissue composition and metabolic
processes in Parkinson’s disease (12 14). The potential for obtaining good spatial local-
ization and high-resolution serial measurements makes in-vivo
1H MRS an ideal
method for investigating biochemical interactions such as the mechanism of neuro-
transmitters (15). This application introduces the possibility of observing major brain
metabolites that contribute to the major resonances seen in 
1H MR spectra of the brain,
such as N-acetylaspartate (NAA), creatine/phosphocreatine (Cr), and choline-contain-
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Ping compounds (Cho). Biochemical information about local
cellular metabolism can be obtained by determining the
metabolite ratios of spectrally detected neurochemicals
(16), and may provide important clues to the pathophysio-
logic status of patients with Parkinson’s disease.
Clinical improvement of Parkinsonian tremor after thala-
motomy might be reflected by the changes in brain metab-
olism seen at 
1H MRS. Functional connectivity between the
thalamus and other motor-related regions such as the basal
ganglia and substantia nigra might also be reflected by the
changes in brain metabolism occurring after thalamotomy.
The purpose of this study is to investigate the utility of
1H MRS in demonstrating changes in regional brain metab-
olism after stereotactic thalamotomy in patients with
Parkinson’s disease.
MATERIALS AND METHODS
Patients
Between August 1998 and September 1999, 15 patients
(seven men and eight women; mean age, 56.5 years) un-
derwent stereotactic thalamotomy for the control of med-
ically refractory parkinsonian tremor. Prior to the proce-
dure, all received levodopa, but this failed to control their
tremors. Three showed no response to the drug, while the
initially good response of the other 12 subsequently de-
clined. Nine patients with predominantly right-sided symp-
toms, and six whose symptoms were predominantly left-
sided underwent, respectively, thalamotomy of the left,
and right, ventralis lateralis. Clinical assessment of all 15
by a neurologist specializing in movement disorders includ-
ed neurologic examination and assignment of a score from
the four-point Tremor Rating Scale (17, 18): 0, absent; 1,
slight, present with action; 2, moderate in amplitude, pre-
sent with action; 3, moderate in amplitude, with posture
holding and action; 4, marked in amplitude, interferes with
feeding. This quantitative assessment was performed pre-
operatively and about 4 months postoperatively. The clini-
cal characteristics of these 15 patients, who underwent uni-
lateral thalamotomy, appear in Table 1.
For the purpose of comparison, 15 age-matched control
subjects [six men and nine women aged 39 64 (mean,
54.8) years], none of whom showed clinical evidence of
neurologic diseases or MR imaging evidence of structural
lesions in the basal ganglia, also underwent MR imaging
and 
1H MRS. Written informed consent was obtained from
all patients and control subjects.
Operative Technique-Thalamotomy
An MRI-compatible stereotactic frame was affixed to the
cranial vault after infiltration of the pin insertion sites with
1% lidocaine. Following frame placement, the patient un-
derwent sagittal T1-weighted MR imaging to identify the
anterior and posterior commissure (AC, PC) and measure
AC-PC length. Next, T1-weighted axial images (TR, 400;
TE, 12; FOV, 30 30; 2 NEX; 3 mm thickness) were ob-
tained through the basal ganglia and thalamus, parallel to
the AC-PC plane. In most cases the AC-PC line was visi-
ble, and could be used for identification of the initial target,
located at a point about 4 5 mm posterior to the mid AC-
PC plane, 13.5 15 mm lateral to the midline, and 0 1 mm
above the level of the intercommissural plane. When the
third ventricle is dilated, it is wise to add 1 2 mm to the lat-
eral dimension.
The patient was placed in a comfortable position and the
frame was fixed to the operating table with the head slight-
ly above the level of the chest. After infiltration of the
scalp with 1% lidocaine, a 2 3 cm parasagittal incision was
made and a burr hole was placed 2.5 cm from the midline
at the level of the coronal suture. The dura was coagulated
and opened and a small pial incision was made, avoiding
any cortical veins, to allow for atraumatic introduction of
the electrode. At this point the stereotactic arc was brought
into position and the electrode guide tube lowered into the
burr hole directly over the pial incision. Macrostimulation
can also be used to delineate the optimal lesion location. A
commercially available lesion generator (Radionics,
Burlington, Mass., U.S.A.) was used for impedance moni-
toring, stimulation and lesion induction. Stimulation in-
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Table 1. Clinical Data of Patients with Parkinson’s Disease
Who Underwent Unilateral Stereotactic Thalamotomy
Patient Age Duration Dominant Side of Preop Postop
No. (yrs)/Sex (yrs) Hand Lesion Tremor Tremor
01 56/F 6 Rt Lt score 3 score 0
02 61/M 8 Lt Rt score 3 score 0
03 62/F 13 Lt Rt score 3 score 0
04 62/F 6 Rt Lt score 3 score 0
05 54/M 5 Rt Lt score 2 score 0
06 57/M 8 Lt Rt score 3 score 0
07 59/F 7 Rt Lt score 4 score 1
08 67/F 13 Rt Lt score 2 score 0
09 58/F 7 Lt Rt score 3 score 0
10 64/M 10 Lt Rt score 4 score 1
11 59/M 6 Lt Rt score 3 score 0
12 59/F 9 Lt Rt score 3 score 0
13 43/F 4 Lt Rt score 2 score 0
14 49/M 6 Rt Lt score 3 score 0
15 54/M 7 Rt Lt score 3 score 0
Note.─ Lt = left, Rt = right,  Tremor Rating Scale scores: 0, absent; 1,
slight, present with action; 2, moderate in amplitude, present with action;
3, moderate in amplitude, with posture holding and action; 4, marked in
amplitude, interferes with feeding,   Left thalamotomy,   Right thalamotomyvolved the use of square wave pulses at 2 3 volts and with
a frequency of 5 Hz to obtain motor thresholds, and at 50
Hz to assess the amelioration of sensory response symp-
toms. Tremor response indicated whether the electrode
was well positioned: low frequency (2 Hz) stimulation
within Vim usually causes tremor increase, whereas high
frequency (50 Hz) stimulation, resulting from good posi-
tioning, causes amelioration. Once the target was con-
firmed, a lesion was generated for 2 minutes at 65 , and
for 2 minutes at 75 , and tremor reduction was substan-
tial. After withdrawing the generator to a point 1mm from
the target, another lesion was induced for 2 minutes at 75
, and the procedure was repeated with the generator 3
mm from target. After induction of this final lesion, the
tremor totally disappeared.
1H MR Spectroscopy
For in-vivo
1H MRS examinations before and after
stereotactic thalamotomy, a clinical 1.5T MRI/MRS system
(GE Signa Advantage, Version 4.8; GE Medical Systems,
Milwaukee, Wis., U.S.A.) with a standard quadrature bird-
cage head coil was used. Localized single voxels (7 8 ml)
centered on the volume of interest regions in the substantia
nigra, thalamus, and putamen were selected using T2-
weighted MR imaging (TR, 2500 ms; TE, 90 ms). The aver-
age follow-up period was four months (range, 14 20
weeks). A stimulated-echo acquisition mode (STEAM) (19,
20) was used for localization; suppression of the water sig-
nal involved the use of a three-pulse chemical shift selec-
tive (CHESS) sequence (21, 22). For optimization of the
homogeneitiy of both total and localized brain volume,
higher order offsets and linear shim coils were adjusted by
auto prescan (APS), which was also used to adjust the
strength of transmitter RF power, receiver gains, and the
three RF pulses used for suppression of the water signal.
After adjustment, typical line width (full width at half max-
imum, FWHM) was usually 2 4 Hz, which provided 97
99% of the suppression factor. Image-guided STEAM spec-
tra were obtained with a TE of 20 msec, TR of 2000 msec,
data points of 2048, spectral bandwidth of 2500 Hz, and
acquisition averages of 128.
Processing
Raw data were transferred to a Sun SPARC Workstation
IPC (Sun Micro Systems, Mountain View, Cal., U.S.A.)
and processed using a SAGE data analysis package (GE
Medical Systems, Milwaukee, Wis., U.S.A.). Postprocess-
ing involved the removal of residual water signal, correc-
tion, if needed, of the heavy eddy current, Lorenz-to-
Gauss transformation, Gaussian line broadening of 0.5 Hz,
zerofilling of 4K, Fourier transformation, and zero-order
phasing of the transformed spectrum. Any resulting spectra
which contained the features of inadequate signal-to-noise
ratio (SNR), outer volume contamination, distorted base-
lines, severe phase distortion due to the heavy eddy cur-
rent, hardware artifacts, or inappropriate suppression of
the water signal were regarded as unacceptable and ex-
cluded from data analysis. Peak areas were derived using
the Marquardt algorithm to fit a Lorenzian type (23).
Resonance peak assignments of major neurometabolites at
in-vivo
1H MRS were NAA at 2.00 ppm, Cr at 3.00 ppm,
and Cho at 3.20 ppm. In all patients and all control sub-
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Fig. 1. Typical T2-weighted axial MR images obtained approximately 4 months after stereotactic thalamotomy show no apparent mor-
phologic abnormalities. Voxels of (A) substantia nigra, (B) thalamus, and (C) putamen of the hemisphere that did undergo surgery were
selected for localized in-vivo
1H magnetic resonance spectroscopy.
ABCjects, the relative ratios of NAA to Cho, NAA to Cr and
Cho to Cr in the substantia nigra, thalamus and putamen
were determined before and after stereotactic thalamoto-
my. We assessed whether clinical improvement of
Parkinsonian tremor after thalamotomy was reflected by
the changes in brain metabolism seen at 
1H MRS, also com-
paring these ratios between control subjects and patients.
Statistics
The software employed for statistical analysis was SPSS
for Windows, Version 6.0 (SPSS, Chicago, Ill., U.S.A.).
Student’s paired-sample t test was used for spectroscopic
data analysis; for multiple comparisons, statistical signifi-
cance was assumed where p was less than 0.05.
RESULTS
All patients with tremor experienced amelioration of
their symptoms on the side contralateral to the thalamoto-
my. Before treatment, three patients scored 2 on the
Tremor Rating Scale, ten had a score of 3, and two had a
score of 4; four months after treatment, 13 patients scored
0 and two scored 1 (Table 1). Complete abolition of tremor
occurred in 87% of patients (13/15), with significant im-
provement in the remaining two.
During the initial postoperative period of about one
week, each patient underwent T2-weighted MR imaging,
and temporary neurological deficits, presumably due to
perilesional edema, were observed in all cases. The deficits
resolved as the edema resolved, and were absent at four-
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Fig. 2. In-vivo
1H magnetic resonance spectra obtained before and
after thalamotomy from selected voxels of (A) substantia nigra, (B)
thalamus, and (C) putamen in patients with Parkinson’s disease.
Cmonth follow-up examination (Fig. 1B). Typical T2-weight-
ed axial MR images, including voxels of the substantia ni-
gra, thalamus and putamen for localized in-vivo
1H MRS
after thalamotomy, are shown in Figure 1. In-vivo
1H MR
spectra were also obtained from the voxels of the substan-
tia nigra, thalamus and putamen, on the most affected side,
before and after thalamotomy (Fig. 2). NAA/Cho ratios for
the substantia nigra, thalamus and putamen are listed in
Table 2, and compared graphically in Figure 3. As can be
seen in Figures 3A and 3B, the differences between them
are substantial. In the substantia nigra of 80% of patients
(12/15) who showed clinical improvement following thala-
motomy, decreased NAA/Cho ratios were observed at se-
lected voxels, and significant metabolic changes in these ra-
tios were apparent after thalamic surgery (p = 0.03). In
67% of patients (10/15) whose clinical condition im-
proved, these ratios were also significantly lower in the
thalamus (p = 0.03). In the putamen, significant statistical
change in the ratios was not established (p = 0.08), though
a significant reduction was noted in 73% of patients
(11/15). Thus, in these 15 cases, NAA/Cho ratios in the
substantia nigra, thalamus and putamen were generally
low following thalamotomy. No significant changes in oth-
er metabolite ratios (NAA/Cr and Cho/Cr) were estab-
lished. Although the mean ratios appear to indicate lower
NAA/Cho for patients than for age-matched controls, t
tests showed that these differences were not statistically
significant.
DISCUSSION
Neuroimaging modalities such as computed tomography
(CT) and MRI are of limited value in distinguishing the
neurodegenerative causes of Parkinson’s disease and, as in
our study, morphologic abnormalities are often not appar-
ent (Fig. 1). In Parkinson’s disease, the presence of iron (or
other paramagnetic) deposition in the putamen may cause
hypointensity at T2-weighted MR imaging, though this is
nonspecific or indistinguishable from the hypointensity
seen in many normal elderly subjects (24, 25).
The results reported in this paper indicate that tremor re-
lief in chronic levodopa-refractory Parkinson’s patients can
be reliably achieved by means of stereotactic thalamoto-
my. Tremor was abolished in 13 of our 15 patients, with
significant improvement in the other two (Table 2), and
overall, 87% of patients showed moderate to marked im-
provement after a mean follow-up period of four months.
These results are consistent with those reported by others
during the pre-carbidopa/levodopa era (26 29) and pro-
vide additional support for the use of thalamotomy for the
treatment of medically refractory tremor. Thalamotomy
had no effect, however, on bradykinesia or other manifes-
tations of Parkinson’s disease such as mental deterioration
and gait disturbance.
In-vivo
1H MRS is a noninvasive method of measuring
important proton metabolites in patients with Parkinson’s
disease, and several MRS investigations of the brain in pa-
tients with this condition have been reported (12 14). All
compared metabolic rates between normal controls and
patients with Parkinson’s disease, and most found that in
those with the disease, differences in the NAA/Cho ratio
were not significant. The studies did not, however, exam-
ine the relationship between regional metabolic changes
and to clinical outcome following surgery. To our knowl-
edge, this is the first study to use 
1H MRS for the follow-up
evaluation of Parkinson’s disease patients who showed
clinical improvement following surgery. Using this tech-
nique, we have demonstrated that NAA/Cho ratios
Baik et al.
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Table 2. Relative Metabolite Ratios Obtained from the Substantia Nigra, Thalamus, and Putamen of Control Subjects and
Patients with Parkinson’s Disease before and after Stereotactic Thalamotomy
Mean SD
Anatomic Site Metabolite Ratio
Controls Patients with Preop Parkinson’s Disease Postop p value
NAA/Cho 1.54 0.38 1.79 0.56 1.34 0.39 0.03
Substantia Nigra NAA/Cr 1.55 0.29 1.70 0.37 1.39 0.34 0.09
Cho/Cr 1.02 0.24 1.04 0.23 1.11 0.29 0.51
NAA/Cho 1.56 0.40 1.57 0.29 1.27 0.32 0.03
Thalamus NAA/Cr 1.28 0.25 1.34 0.17 1.16 0.27 0.43
Cho/Cr 0.82 0.18 0.85 0.21 0.92 0.27 0.48
NAA/Cho 1.82 0.44 1.85 0.46 1.44 0.35 0.08
Putamen NAA/Cr 1.32 0.28 1.41 0.28 1.18 0.27 0.12
Cho/Cr 0.77 0.14 0.83 0.19 0.91 0.25 0.64
Note.─ NAA = N-acetylaspartate, Cr = creatine, Cho = choline-containing compounds,  In patients with Parkinson’s disease, statistical significance was
determined using Student’s paired t test before and after thalamotomy. A p value of less than 0.05 was considered significant.showed generally low levels in the substantia nigra, thala-
mus and putamen of such patients.
Compared with pre-thalamotomy values, the observed
changes in NAA/Cho ratios in these patients were substan-
tial (Fig. 3). Among those who underwent thalamotomy,
decreased ratios were observed in the substantia nigra and
thalamus of 80% (12/15) and 67% (10/15), respectively. It
was not statistically established that surgery led to signifi-
cant change in the ratio, though the reduction observed
tended to be significant in 73% of patients (11/15). 
The results of this study indicate that significant postop-
erative metabolic reduction of NAA/Cho ratios occurred in
portions of the substantia nigra, thalamus and putamen of
the hemisphere that did undergo surgery. Metabolic
change occurred, in other words, in Parkinson’s disease pa-
tients whose clinical condition improved. Table 2 shows
that these changes were consistent in the substantia nigra,
thalamus and putamen contralateral to the most affected
side. The surgical changes induced by thalamotomy may
directly affect the specific regional brain networks associat-
ed with clinical manifestations of parkinsonism.
Loss of dopaminergic inputs to the striatum associated
with degeneration of the nigrostriatal pathway decreases
the activity of inhibitory striatal neurons (predominantly
D2 receptors) and increases the activity of others (predom-
inantly D1 receptors). The former neurons project directly
to the globus pallidus interna, and the latter mainly to the
globus pallidus externa and subthalamic nucleus. The
mechanism of action of thalamotomy is not known but
may involve the destruction of autonomous neural activity,
that is, of synchronous bursts that fire at the same frequen-
cy as limb tremor. Lenz et al. (30) reported that a small le-
sion which targets tremor cells (neurons that fire at tremor
frequency) is uniformly effective in relieving parkinsonian
tremor. Two major pathways are interrupted by a thalamic
lesion: the pallidofugal, which arises from the globus pal-
lidus interna and enters the inferior part of the ventralis
oralis nucleus via the ansa lenticularis, and the contralater-
al pathway, which arises from the cerebellum. The ven-
tralis intermedius (Vim) projects to the motor cortex, and
as a result of the connections involved could become pas-
sively entrained by oscillations throughout the motor sys-
tem. Thus, lesions in the Vim would reduce tremor by cur-
tailing this entrainment; thalamotomy plays this role, inter-
rupting the passive entrainment of Vim by distant struc-
tures, and thus its inherent rhythmicity. Hence, we suppose
that the pathophysiologic mechanisms generated in the se-
lected regions may be directly related.
Considerable effort has been invested in attempting to
elucidate the role of NAA in cerebral metabolism (31, 32).
Although its exact function is still unknown, there is strong
evidence, especially from investigations of human brain tu-
mors (33, 34), tumor extracts (35), and studies of extracts
from cultured cells (36), to suggest that this compound is
limited solely to neurons. Furthermore, it has been shown
that lesions produced by specific neurotoxic agents lead to
reductions in NAA (37). NAA has therefore been used as a
marker of neuronal integrity, and it has been suggested
that the NAA reductions seen at proton MRS are sec-
ondary to neuronal loss in cerebral pathology as exempli-
fied by stroke (38), acquired immunodeficiency syndrome
(AIDS) (39), multiple sclerosis (40, 41), demyelinating dis-
eases (39), and diabetes mellitus (42). NAA reductions at-
tributed to neuronal degeneration have been further veri-
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Fig. 3. Comparison of NAA/Cho ratios obtained before and after thalamotomy from selected voxels of (A) substantia nigra, (B) thalamus,
and (C) putamen in patients with Parkinson’s disease. The results indicate significant postoperative metabolic reduction in NAA/Cho ra-
tios in the substantia nigra, thalamus, and putamen of the hemisphere that did undergo surgery.
AB Cfied by a large database derived from using temporal lobe
epilepsy (44), AIDS (45), and Alzheimer’s disease cases
(46).
Our analysis of the combined data from all patients
showed a decreased NAA/Cho ratio in the substantia nigra
and thalamus of Parkinson’s disease patients. Although we
feel that in this study the ratio of NAA/Cho peak area
measurements reflects a significant decrease in NAA itself,
we acknowledge the possibility that increased Cho levels
also account for the decreased NAA/Cho ratios. A reduced
NAA/Cho ratio may, in other words, be interpreted as ei-
ther decreased NAA, reflecting neuronal loss, or increased
Cho, presumably reflecting gliosis (47, 48). A further inter-
pretation is that both NAA and Cho are affected early in
the surgical process, and it is this combination that allows
the significant difference to be detected. Our present result
suggests that since changes in the NAA/Cho ratio may be
related to clinical improvement following surgery, the ratio
may be a valuable criterion for the evaluation of
Parkinson’s disease. Because significant metabolic change
was demonstrated in patients with Parkinson’s disease, 
1H
MRS may be a more sensitive diagnostic tool than MRI in
monitoring the progressive change occurring in such pa-
tients. 
Additional analysis of the data presented in Table 2
showed a trend toward slightly decreased NAA/Cho and
NAA/Cr ratios in the putamen, whereas Cho/Cr was with-
in the normal range. These findings may indicate slightly
decreased NAA and unaffected Cho and Cr levels, or al-
ternatively, they may indicate that increased Cho and Cr
levels lead to decreased NAA/Cho and NAA/Cr ratios,
and a normal Cho/Cr ratio. Absolute quantification of the
metabolites involved would resolve this question. For the
present, however, we cannot exclude the possibility that
neuronal reduction in the putamen of PD patients might be
sufficient for MRS examination to reveal significantly de-
creased NAA levels.
Although thalamotomy has gained renewed acceptance
as a treatment for advanced Parkinsonism, the pathophysi-
ology of improved motor function following surgery is not
fully understood. However, the present study has shown
that 
1H MRS centered on the substantia nigra, thalamus
and putamen in carefully selected Parkinson’s disease pa-
tients reveals a consistent, reproducible, and significant re-
duction in the NAA/Cho ratio, which is most likely to re-
flect changes in NAA itself. Decreased NAA/Cho ratios
may reflect neuronal loss, and we suggest that thalamic ab-
lation may have metabolic consequences for beyond the
lesion site. Moreover, postsurgical clinical improvement
may in part be predicated by these metabolic changes,
which although remote, may be critical determinants of
therapeutic success.
Bowen et al. (49) reported that in patients with
Parkinson’s disease, the lactate signal was elevated, a find-
ing which might support the hypothesis that mitochondrial
electron transport chain deficits and a concomitant increase
in free radical generation due to defects in oxidative phos-
phorylation are present in brain tissue in Parkinson’s dis-
ease, and that associated lactate elevation is a sign of meta-
bolic stress (50). Neither before nor after surgery, howev-
er, were we able to demonstrate a lactate signal in substan-
tia nigra, thalamus, or putamen tissue in either controls or
Parkinson’s disease patients, and this has also been the
finding of other studies (12, 51 53).
In conclusion, the present study suggests that by high-
lighting metabolic variation, particularly that of the
NAA/Cho ratio, water-suppressed in-vivo
1H MRS may
help provide a better understanding of the pathophysiolog-
ic process occurring in patients with Parkinson’s disease.
Indeed, an understanding of the functional basis for surgi-
cal response may have great importance in the design of
new treatment strategies for Parkinson’s disease and relat-
ed disorders. Investigation of the MR spectral alterations
seen at after a long-term follow-up examination in patients
with Parkinson’s disease can provide the basis for the fur-
ther detailed analysis required.
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